Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Abstract Background Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patien...

Full description

Bibliographic Details
Main Authors: Armin Scheffler, Olga Messel, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Steffen Naegel, Dagny Holle
Format: Article
Language:English
Published: BMC 2020-07-01
Series:The Journal of Headache and Pain
Subjects:
1. migraine
2. erenumab
3. therapy
4. real-world
5. CGRP antibody
Online Access:http://link.springer.com/article/10.1186/s10194-020-01151-0

Internet

http://link.springer.com/article/10.1186/s10194-020-01151-0

Similar Items